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Abstract: A monomeric basic PLA2 (PhTX-II) of 14149.08 Da molecular weight was 
purified to homogeneity from Porthidium hyoprora venom. Amino acid sequence by  
in tandem mass spectrometry revealed that PhTX-II belongs to Asp49 PLA2 enzyme class 
and displays conserved domains as the catalytic network, Ca2+-binding loop and the 
hydrophobic channel of access to the catalytic site, reflected in the high catalytic activity 
displayed by the enzyme. Moreover, PhTX-II PLA2 showed an allosteric behavior and  
its enzymatic activity was dependent on Ca2+. Examination of PhTX-II PLA2 by CD 
spectroscopy indicated a high content of alpha-helical structures, similar to the known 
structure of secreted phospholipase IIA group suggesting a similar folding. PhTX-II PLA2 
causes neuromuscular blockade in avian neuromuscular preparations with a significant direct 
action on skeletal muscle function, as well as, induced local edema and myotoxicity, in mice. 
The treatment of PhTX-II by BPB resulted in complete loss of their catalytic activity that 
was accompanied by loss of their edematogenic effect. On the other hand, enzymatic activity 
of PhTX-II contributes to this neuromuscular blockade and local myotoxicity is dependent 
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not only on enzymatic activity. These results show that PhTX-II is a myotoxic Asp49 PLA2 
that contributes with toxic actions caused by P. hyoprora venom. 
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1. Introduction 
Snakes of the genus Bothrops (including Porthidium and Botriopsis) represent the ophidian fauna of 
great scientific and medical interest in Brazil, since they are responsible for most cases of deadly snake 
bites which occur in the country [1,2]. Porthidium hyoprora is a representative of this group of venomous 
snakes; their habitat is the Amazon tropical forest in Brazil, Ecuador, Peru and Colombia [3]. Proteomic 
analysis of P. nasutum and P. ophryomegas snake venom and the characterization of toxins from  
P. lansbergii hutmanni [4,5] have already been performed. However, minimum attention has been paid 
to the characterization of P. hyoprora venom. This snake is named Amazonian hog nose pit viper,  
whose venom has high phospholipase A2 activity and induces drastic local myotoxicity [6]. 
The phospholipase A2 (PLA2) superfamily consists of a broad range of enzymes defined by their 
ability to catalyze the hydrolysis of the middle (sn-2) ester bond of substrate phospholipids [7]. This 
family of proteins can be found in the mammalian pancreas and also in the venoms of snakes, scorpions 
and bees. Snake venoms contain plural PLA2 isozymes which show wide variety of physiological 
activities such as neurotoxicity, myotoxicity, cardiotoxicity, platelet aggregation induction or inhibition, 
edema, hemolysis, anti-coagulation and hypotension [8]. A PLA2 may have more than one specific 
physiological activity, and therefore, it may play multiple roles in the overall effects of envenoming [9]. 
Significant advances were performed in the efforts to characterize and understand venom PLA2; 
however, many aspects of the structure and function of PLA2 present in snake venoms are still a mystery, 
and new enzymes present in less studied venoms need to be discovered and characterized [10]. A goal 
of our studies is to characterize the toxins from P. hyoprora snake venom, steered by the development 
and refinement of chromatographic and mass spectrometry techniques, given that the isolation and 
characterization of individual venom components constitutes the mainstay of toxinology, as a key 
strategy to dissect and to analyze the complex series of events involved in envenoming [9]. 
In a previous work, we showed that P. hyoprora snake venom is a rich source of PLA2 enzymes,  
and also, PhTX-I PLA2 was purified and characterized [6,11]. In the present study, we expand on this 
pit viper by analyzing one novel myotoxic Asp49 PLA2 (PhTX-II) isolated and sequenced by tandem 
mass spectrometry. Further, our study provides an insight into the biochemical and pharmacological  
properties of this basic PLA2, and suggests that it exerts its myotoxic action by both enzymatic and  
non-enzymatic mechanisms. 
2. Results 
2.1. Purification and Biochemical Characterization of PhTX-II 
One myotoxic PLA2 was identified and isolated from P. hyoprora venom by successive reverse phase 
high performance liquid chromatography (RP-HPLC) separations. The fractionation of P. hyoprora 
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venom using a C18 analytical column produced approximately 20 major peaks (Figure 1). Peak 11 
eluting at 62.34% of buffer B and 36.4 min, was positive for PLA2 and myotoxic activities and was 
named PhTX-II PLA2. Homogeneity of the purified protein was demonstrated by re-chromatography on 
an analytical RP-HPLC C18 analytical column, showing the presence of only a peak, (data not shown) 
and by Tricine SDS-PAGE under non-reducing and reducing conditions revealing a unique band with 
Mr about 14 kDa each (Figure 1 insert). 
Figure 1. Chromatographic and electrophoretic profile of Porthidium hyoprora venom 
fractioning on a µ-Bondapack C18 column, monitoring elution profile at 280 nm. 
Emphasized in black is fraction 11 (*) characterized as PhTX-II PLA2; Insert: 
Electrophoretic profile in Tricine SDS-PAGE (1) Molecular mass markers; (2) PhTX-II not 
reduced; (3) PhTX-II reduced with DTT (1 M). 
 
Figure 2. Mass determination of PhTX-II PLA2 by mass spectrometry using a Q-Tof Ultima 
API ESI/MS (TOF MS mode). The MH+ and MH2++ species are shown. 
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The fraction PhTX-II has a molecular mass of 14149.08 Da, as ascertained by Q-Tof Ultima API 
ESI/MS (TOF MS mode) mass spectrometry, the MH+ and MH2++ species are also shown (Figure 2). 
This value of molecular mass was used in calculating the molar concentrations of toxin used in the 
experiments described below. 
2.2. Determination of the Amino Acid Sequences of PhTX-II 
The alkylated PhTX-II was digested with trypsin and its tryptic peptides were detected and 
characterized by mass spectrometry. The overall sequences for each peptide were then determined by 
ESI-MS/MS sequencing. No discrimination between the isobaric residues isoleucine and leucine in any 
of the sequences reported since they were indistinguishable in low energy CID spectra. Because of the 
external calibration applied to all spectra, it was also not possible to resolve the 0.036 Da difference 
between glutamine and lysine residues, except for the lysine that was deduced based on trypsin digestion. 
Table 1. Sequence obtained by MS/MS based on the alkylated tryptic peptides derived.  
The peptides were separated and sequenced by mass spectrometry. (Start, End: Amino acid 
position in the protein sequence. Observed, expected and calculated mass of peptides). 






1 7 438.731 875.449 875.486 −0.037 NL/IL/IQFNK(M) 
8 15 468.250 934.486 934.515 −0.029 (K)ML/IL/IKETGK(N) 
16 33 1079.967 2157.921 2157.918 0.002 (K)NAL/IPFYAFYGCYCGWGGR(G) 
34 42 571.690 1140.521 1140.552 −0.030 (R)GKPKDKTDDR(C) 
43 53 753.247 1504.479 1504.535 −0.055 (R)CCFVHDCCYGK(L) 
54 60 300.403 599.304 599.310 −0.005 (K)L/ITGCPK(W) 
61 69 592.800 1183.586 1183.591 −0.004 (K)WDL/IYPYSL/IK(S) 
70 77 443.181 884.349 884.406 −0.057 (K)SGYL/ITCGK(G) 
78 90 871.806 1741.598 1741.649 −0.051 (K)GTWCEEQL/ICECDR(A) 
91 97 404.713 807.411 807.406 0.005 (R)AAAL/ICFR(E) 
98 105 498.741 995.468 995.456 0.012 (R)ENL/IDTYNK(Y) 
106 115 649.761 1297.508 1297.543 −0.035 (K)YGYMFYPDSR(C) 
116 123 483.172 964.330 964.374 −0.043 (R)CKGPSEQC- 
Table 1 shows the deduced sequence and measured masses of alkylated peptides obtained.  
After tryptic digestion of PhTX-II protein, 13 peptides were found. Each sequenced peptide was 
submitted to the NCBI database, using the protein search program BLAST-p. Using the position matches 
of the sequenced peptides with phospholipase A2 family present in the database, it was possible to deduce 
their original position on the protein PhTX-II. 
Mass spectra containing the y-ion series of the third and fourth peptides and amino acid sequences at 
positions 16–33 and 43–53, respectively, are shown in Figure 3. The fourth peptide (Figure 3B) has the 
sequence CCFVHDCCYGK showing an Asp residue at position 49 of the primary structure of the 
protein, suggesting that this protein belongs to the family of PLA2 Asp49 catalytically active.  
The sequence NAL/IPFYAFYGCYCGWGGR of a third peptide (Figure 3A) show amino acid positions 
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(G)25, (Y)27 (G)29 (G)31 which are part of the calcium-binding, highly conserved domain in PLA2 
Asp49 and whose presence is required for catalytic activity. 
Figure 3. MS/MS spectrum of the tryptic peptides of m/z 2157.9189 (A) and 1504.54 (B); 
Series of y fragment ions of 11-residue-long tryptic peptide (CCFVHDCCYGK) containing 
the aspartic acid residue at position 49 (*) in the amino acid sequence (B) and Ca2+-binding 
loop NAL/IPFYAFYGCYCGWGGR, highly conserved region in the amino acid sequences 
of PLA2 (A). 
 
The amino acid sequence of PhTX-II PLA2 was compared with other sequences of myotoxics PLA2 
already determined and recorded in the database (Figure 4A). By homology PhTX-II is composed of 
123 amino acid residues and the arrangement of the cysteines, indicates that PhTX-II belongs to the 
group IIA PLA2. The comparison of PhTX-II amino acid sequence with other published sequences 
showed a high degree of homology with LmTX-I PLA2 (84.9%) and Cdr12 (75.4%). In the case of the 
PhTX-I PLA2 from the same venom, 65% homology was observed. The amino acid sequence analysis 
revealed that PhTX-II had a strong evolutionary relationship with BbTX-III (Figure 4B). 
  
Toxins 2014, 6 3082 
 
 
Figure 4. (A) Alignment of the amino acid sequence of the PhTX-II PLA2 with D49-PLA2 
by Edit Seq version 5.01© Program (DNASTAR Inc., Madison, WI, USA, 2001). LmTX-I 
from Lachesis muta muta (P0C942.1) [12]; Cdr12 from Crotalus durissus ruruima 
(P0CAS3.1) [13]; Piratoxin III from Bothrops pirajai (1GMZ_A) [14]; PhTX-I from 
Porthidium hyoprora [6]; BmTX-I from Bothrops moojeni (P0C8M1) [15]; BthTX-II from 
Bothrops jararacussu (2OQD_B) [16]; BbTX-III from Bothrops brazili [17]. The asterisk 
corresponds to Asp49 position; the program introduces gaps to maximize alignments;  
(B) Phylogeny relationship of PhTX-II to other PLA2 isoforms statistically evaluated by 
Bootstrap method. 
 
Figure 5 shows the CD spectrum of PhTX-II PLA2 which demonstrate two negative bands of similar 
magnitude at 208 and 222 nm (−10.000, −9500 deg.cm2.dmol−1) and a positive one at ~190 nm, 
indicating a consistent content of α-helical structures. Based on the CDNN program analysis of the 
PhTX-II PLA2 spectrum, the contents of α-helices, β-sheets and β-turns were 30.5%, 18.2% and  
16.9%, respectively. 
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Figure 5. Far-UV circular dichroism spectra of PhTX-II PLA2. 
 
2.3. Activity Measurements of PhTX-II 
The PLA2 activity was examined using the synthetic substrate 4-nitro-3-(octanoyloxy) benzoic acid 
and was higher in PhTX-II PLA2 (9.65 ± 0.65 nmols/min/mg) when compared with the whole venom 
(5.49 ± 0.71 nmols/min/mg) (Figure 6A). Under the conditions used, PhTX-II PLA2 showed a discrete 
sigmoidal behavior (Figure 6B). Maximum enzyme activity occurred at pH 8.0 and the temperature 
optimum was 40 °C (Figure 6C,D). PhTX-II showed a strict dependence on calcium ions for full activity. 
The addition of Mg2+, Mn2+, Cd2+ and Zn2+ (10 mM) in the presence of low Ca2+ concentration (1 mM) 
decreases the enzyme activity and the substitution of Ca2+ by Mn2+, Cd2+ and Zn2+ reduced the activity 
to levels similar to those in the absence of Ca2+ (Figure 6E). The incubation of PhTX-II with crotapotins 
F2 and F3 from C. d. collilinetaus and EDTA diminished the enzymatic activity; heparin did not 
significantly inhibit this activity. On the other hand, the enzymatic activity of PhTX-II PLA2 was almost 
completely abolished by p-bromophenacyl bromide (BPB) (Figure 6F). 
2.4. Pharmacological Activities of PhTX-II 
PhTX-II PLA2 produced irreversible time- and concentration-dependent neuromuscular blockade in 
indirectly stimulated biventer cevicis preparations, with complete blockade occurring after 110 ± 2 min 
at the highest concentration (1.4 μM); The times required for 50% blockade were 53.47 ± 3.2,  
26.7 ± 2.4 and 17.9 ± 6.5 min for PhTX-II concentrations of 0.35, 0.7 and 1.4 μM, respectively  
(Figure 7A). Pretreatment of PhTX-II with BPB decreased dramatically the neuromuscular blockade by 
this toxin (Figure 7A). At concentrations of 0.35 and 0.7 μM, there were no consistently significant 
changes in the contractures to exogenous ACh and KCl after complete neuromuscular blockade by 
PhTX-II; however, incubation with 1.4 μM decreased the muscle contractures to exogenous ACh and 
KCl, with 75.3% ± 9.4% and 77.7% ± 5.30% of the response remaining at the end of the experiment, 
respectively (Figure 7B). Figure 7C shows a representative recording of the neuromuscular blockade 
produced by PhTX-II PLA2 (1.4 μM) under indirect stimulation at 37 °C. The injection of PhTX-II PLA2 
by the intramuscular (i.m.) route induce significant increment of plasma CK levels at doses 5, 20 and  
50 µg. Time-course analysis showed a maximum increase in plasma CK 3–6 hours after injection, 
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returning to normal by 24 h (Figure 8A). Three hours after treatment started, the myotoxic effect of 
PhTX-II PLA2 was reduced in 82%, by treatment with BPB (Figure 8A). On the other hand, PhTX-II 
PLA2 (2, 5, and 10 μg/paw) also induced moderate footpad edema, compared to PBS-injected animals. 
Edema reached its highest point after 1 h, and receded to normal levels after 24 h, but this effect was not 
observed in case of BPB-inactivated enzyme (Figure 8B). 
Figure 6. (A) PLA2 activity of P. hyoprora venom and PhTX-II PLA2 (B) Effect of substrate 
concentration on the PLA2 activity of PhTX-II; (C) Effect of pH on the PLA2 activity of 
PhTX-II; (D) Effect of temperature on the PLA2 activity of PhTX-II; (E) Influence of ions 
(10 mM each) on PLA2 activity of PhTX-II in the absence or presence of 1 mM Ca2+;  
(F) Effect inhibitory of heparin, EDTA crotapotins (F2 and F3) and chemical modification 
with BPB on PLA2 activity of PhTX-II. In each case, the concentration of PhTX-II was 5 μM. 
The results of all experiments are the mean ± SEM of three determinations (p < 0.05). 
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Figure 7. Neuromuscular blockade of chick biventer cervicis preparations incubated with 
PhTX-II PLA2 (0.35, 0.7, 1.4 μM and modified with BPB) at 37 °C (A). Panel B shows the 
effect of PhTX-II PLA2 on muscle contractures evoked by KCl and acetylcholine (ACh). 
Panels C shows a representative recording from a preparation treated with 0.7 μM of  
PhTX-II PLA2. Tissue responses to KCl (  20 mM) and acetylcholine (ACh,  110 μM) 
were obtained before and after toxin addition. The points are the mean ± SEM of six 
experiments. * (p < 0.05) compared to the twitch-tension before toxin addition. 
 
Figure 8. Time-course of the increments in plasma CK activity after intramuscular injection 
of PhTX-II PLA2 (5.20, 50 μg and modified with BPB/100 μL) in mice. Controls were 
injected with 100 μL of PBS. At different times, blood was collected, and serum levels were 
measured. Values are means ± SEM of five mice at each time point (A); Edema-forming 
activity of PhTX-II PLA2 (2.5, 10 μg and modified with BPB/50 µL) in mice. Edema by 
toxin was injected s.c. in the footpad of mice. At various time intervals the increase in 
footpad volume, as compared to controls, was expressed as percent edema (B). Each point 
represents the mean ± SEM of five animals. 
 




The presence of abundant PLA2 from snake venom as multiple isoenzymes is a common  
observation [9,18]. These isoenzymes in addition to their involvement in the digestion of prey, exhibit a 
wide variety of pharmacological/toxic effects by interfering in normal physiological processes of 
prey/victims [19]. We have previously described the biochemical characterization and some biological 
activities of PhTX-I, a basic PLA2 isolated from P. hyoprora that induces muscle damage in  
mice (leading to CK release) and is pro-inflammatory, causing edema [6]. However, many more  
components of this venom need to be isolated, and to be characterized [10]. This work describes the 
biochemical/pharmacological characterization of PhTX-II, a PLA2 isolated from P. hyoprora venom by 
a single chromatographic step, including reverse-phase chromatography (Figure 1). 
The PhTX-II PLA2 is an enzyme composed of a unique polypeptidic chain revealed by Tricine  
SDS-PAGE with molecular mass of 14,149.08 Da confirmed by mass spectrometry (Figure 2).  
This value is similar to other isolated myotoxic PLA2 from snake venom [20–22]. 
PhTX-II is composed of 123 amino acid residues and the arrangement of the cysteines indicates that 
PhTX-II belongs to group IIA PLA2. As Leu (L) and Ile (I) are indistinguishable with MS/MS analysis, 
it is essential to determine completely the primary structure of PhTX-II PLA2 by protein sequencer or 
cDNA analysis. Amino acid sequence of PhTX-II showed the presence of Asp at position 49 (Figure 4), 
this finding place for the PhTX-II within the catalytically active enzymes, consistent with a lot of PLA2 
purified from viperid snake venoms where Asp49 appears so far to be an absolutely conserved  
position [12,23–25]. The presence of an aspartic residue at 49 position allow the interaction with the ion 
calcium (Ca2+-dependence) and together with Tyr28, Gly30 and Gly31 form the Ca2+-binding loop [26]. 
The His48 is in a key position since it participates in the PLA2 active site as a catalytic residue together 
with Tyr52 and Asp99 [27]. PhTX-II PLA2 displays residues forming the catalytic network and the  
Ca2+-binding loop (Figure 3A,B), reflected in the high catalytic activity displayed by the enzyme. 
In addition, PLA2 enzymes present a hydrophobic channel that provides access to the catalytic site 
((L)2, (W/F)3, (I)9, (Y)22, (C)29, (C)45 and (A)93) are important for the enzymatic activity and 
biological profile of snake venom PLA2 [28]. Tyr73 and Lys56 also indirectly participate in the 
stabilization of the catalytic site of Asp49 PLA2 [29]. All these amino acids are conserved in the  
PhTX-II PLA2, allowing the lipidic substrate access to the catalytic site of the enzyme. 
The comparison of PhTX-II amino acid sequence with other published sequences (Figure 4A) showed 
a high degree of homology with LmTX-I PLA2, Cdr12, and Piratoxin III. Curiously, PhTX-I-another 
PLA2 isolated from P. hyoprora venom [6] share 65% homology with PhTX-II, revealing evolutionary 
distance greater than the other PLA2 isoforms (Figure 4B). These observations probably are due to that 
exons in PLA2 genes mutate faster than introns, and this accelerated evolution of exons plays a 
significant role in the emergence of new isoenzymes by altering the target specificity. Similar results 
were found with Bothrops leucurus and Bothrops asper [9,20,24]. 
After determining the primary structure, PhTX-II was analyzed by CD to check the status folding 
through the quantification of secondary structure. Examination of PhTX-II PLA2 by CD spectroscopy 
indicated a high content of alpha-helical structures, similar to the known structure of secreted 
phospholipase IIA group [30], suggesting a similar folding. The contribution of 30.5% of the α-helix 
structure (Figure 5) is consistent with the crystal structure of PLA2 snake venom, where the presence of 
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three α-helices is demonstrated, which are part of the N-terminus and the hydrophobic channel of access 
to catalytic site, these regions being related with important roles for catalysis as well as pharmacological 
activities [29]. 
The enzymatic activity of PhTX-II PLA2 was confirmed using the 4-nitro-3-octanoyloxy-benzoic acid 
as substrate, and showed a high catalytic activity (9.65 ± 0.65 nmoles/min/mg) (Figure 6A) when 
compared with Bj-V (3.49 ± 0.227 nmoles/min/mg) an Asp49 basic and myotoxic PLA2 purified from 
B. jararacusuu venom [31]. The optimum temperature was around 37 °C, but at 40–45 °C, the  
PhTX-II PLA2 activity did not present a huge decrease (Figure 6D). Like other PLA2, PhTX-II is 
relatively resistant to heat [12,19]. Highest enzymatic activity occurs at pH 8 (Figure 6C). At low 
concentrations of substrate, PhTX-II showed a discrete sigmoidal behavior, as well as BbTX-III and 
Bbil-TX (purified from Bothrops brazili and Bothriopsis bilineata, respectively) that showed similar 
behavior towards this non-micellar substrate [17,21]. We can suggest that the specificity of the 
enzyme/substrate interaction for PhTX-II pointed to a structural resemblance of this enzyme with those 
PLA2 that also had similar behavior with the substrate mentioned above. 
The dependence on Ca2+ ions for full enzymatic activity of PLA2 was previously described by  
Scott et al. [26]. PhTX-II was a typical Ca2+-dependent PLA2 that was less active in the presence of other 
divalent cations (Mg2+, Mn2+, Cd2+, Zn2+) (Figure 6E). This can be explained by coordination geometries 
assumed by the tetrahedral intermediate due to the presence of Ca2+ ions, which determine the 
electrophilic behavior of the catalytic site [29]. However, Mg2+ ions support a significant catalytic 
activity. These results can be attributed to differences in coordination geometry and indicate a 
noteworthy plasticity of the active site environment. 
Incubation of PhTX-II with EDTA diminished the enzymatic activity (Figure 6F), since PLA2 
enzymes require Ca2+ for their activity, chelators such as EDTA inhibit their enzymatic activity and 
which affects normal functions of the PLA2 enzymatic system [32]. The crotapotins are pharmacologically 
inactive and non-catalytic acidic proteins that specifically bind to the PLA2 of different sources 
(pancreas, bee, snake venom) and inhibit its catalytic activity [33]. F2 and F3 crotapotins from  
C. d. collilineatus significantly inhibited the enzymatic activity of PhTX-II by approximately 60% 
(Figure 6F). These results are in agreement with reports of BjIV PLA2 from B. jararacussu, which was 
inhibited by 50% in its catalytic activity by F7 crotapotins from C. d. terrificus, F3 and F4 from  
C. d. collilineatus and C. d. cascavella [31]. Heparin slightly decreased enzymatic activity of PhTX-II; 
similarly, this polyanionic compound also became a negative allosteric modulator of PLA2 of  
C. d. cascavella [34]. 
The treatment of PhTX-II PLA2 by BPB resulted in complete loss of their catalytic activity  
(Figure 6F). The His48 is in a key position since it participates in the PLA2 active site as a catalytic 
residue [29], since the enzymatic activity of the PhTX-II was completely abolished after this 
modification, His48 was likely the residue modified, because this amino acid is part of the catalytic triad 
of this protein family. His-modified enzymes are suitable for both in vitro and in vivo systems in order 
to study the role of the enzymatic activity on the PLA2 pharmacological profiles [11,35,36]. 
Skeletal muscle necrosis is a frequent and serious consequence of snakebite envenoming, potentially 
leading to permanent loss of tissue and disability [37]. In a previous work, we showed that P. hyoprora 
venom cause intense local myotoxicity, inflammation and cytotoxicity [6]. Neuromuscular paralyzing, 
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edematogenic and myotoxic activities were investigated, in order to understand the contribution of 
PhTX-II PLA2 in the myotoxic effect of P. yoprora. 
As shown here, PhTX-II PLA2 causes time- and concentration-dependent neuromuscular blockade in 
avian nerve–muscle preparations. With 1.4 and 0.7 μM of PhTX-II, fifty percent blockade occurred 
before 30 min, while blockade with minor concentration (0.35 μM) occurred after 50 min (Figure 7A).  
In addition to the neuromuscular blockade, slight muscle contracture (increase in baseline tension) was 
observed with the highest concentration (1.4 μM) (Figure 7C). Moreover, neuromuscular block produced 
by PhTX-II at the same concentrations was accompanied by diminution of responses to potassium (KCl) 
and acetylcholine (ACh) (Figure 7B). These observations suggest damage caused to muscle membrane 
and nicotinic receptors in the post-synaptic membrane. The presence of myotoxic components in the 
venom are shown to reduce the response of a skeletal muscle to direct electrical stimulation or exposure 
to high concentrations of K+ and/or initiate muscle contracture [38]. 
Incubation with BPB inhibited enzymatic activity of PhTX-II and dmarkedly decreased toxin-induced 
neuromuscular blockade (around 89%) in chick biventer cervicis preparations (Figure 7A) strengthening 
the hypothesis that phospholipid enzymatic hydrolysis is involved in this effect. Similarly, neurotoxic 
activity was inhibited almost completely after alkylation of His48 of Bbil-TX PLA2 from  
Bothriopsis bilineata, Cdc-9 and Cdc-10 PLA2 from (Crotalus durissus cumanensis and PhTX-I from 
P. hyoprora [11,39,40]. 
It was pointed out by Francis et al., [41] that myotoxic proteins from snake venoms have a set of three 
or four tyrosine residues between positions 114 and 124; PhTX-II PLA2 have four tyrosine residues in 
this region, which is reflected in their high myotoxicity. PhTX-II markedly increased plasmatic creatin 
kinase (CK) levels after being injected into the gastrocnemius muscle of mice; this increase in CK shows 
severe muscle damage in muscle fibers injected with the toxin, leading to alocal myotoxic effect  
(Figure 8A). Theplasmatic increased of CK observed at different time intervals when there is 
phospholipid hydrolysis suggests that phospholipid degradation is an initial event that leads to membrane 
perturbation, resulting initially in increased permeability to ions and small molecules, such as Ca2+, K+ 
and ATP, and afterwards to large membrane lesions through which proteins such as CK are released [42]. 
Previous studies suggest that catalytic activity plays a key role in the myotoxicity induced by  
Asp49 PLA2 myotoxins [36]. However, after chemical modification with BPB, PhTX-II PLA2 yielded 
18% myotoxic activity in mice, thus PhTX-II-induced local myotoxicity is dependent not only on 
enzymatic activity. 
The Asp49 PLA2 myotoxins, besides causing muscle necrosis, have been shown to promote marked 
local inflammatory events in several experimental models [21,43,44]. The sub plantar injection of this 
PhTX-II PLA2 also caused mouse paw edema (Figure 8B). In addition, the treatment of PhTX-II by BPB 
resulted in complete loss of their catalytic activity that was accompanied by loss of their edematogenic 
effect. The mechanism by which catalytically active PLA2 induce edema may be explained by 
phospholipid hydrolysis, probably due to liberation of precursors of a variety of eicosanoids and platelet 
activator factors [33]. Thus, MT-III a Asp49 PLA2 from Bothrops asper induces cyclooxygenase-2 
expression and prostaglandin E2 production via activation of NF-κB, p38MAPK, and PKC in 
macrophages [44]. 
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4. Materials and Methods 
4.1. Venom and Reagents 
The venom and the solvents (HPLC grade), 4-nitro-3-(octanoyloxy) benzoic acid, sequence grade 
bovine pancreatic trypsin, 2,4’-Dibromoacetophenone (BPB) and other reagents were from Sigma 
Chemical Co. (St. Louis, MO, USA). The animals and research protocols used in this study followed  
the guidelines of the Ethical Committee for use of animals of ECAE-IB-UNICAMP SP, Brazil  
(protocol number 1860-1) and international law and policies. 
4.2. Purification of PhTX-II 
The PhTX-II PLA2 from P. hyoprora venom was purified by reverse phase HPLC using 500 mg of 
whole venom, according to the method described by Ponce-Soto et al., [45]. Briefly, 5 mg of whole 
venom was dissolved in 200 µL of buffer A (0.1% TFA) and centrifuged at 4500 g, the supernatant was 
then applied to a µ-Bondapack C18 column (0.78 × 30 cm; Waters 991-PDA system), previously 
equilibrated with buffer A for 15 min. The elution of the protein was then conducted using a linear 
gradient (0%–100%, v/v) of buffer B (66.5% Acetronitrile in buffer A) at a constant flow rate of  
1.0 mL/min. The chromatographic run was monitored at 280 nm of absorbance and the PLA2  
active fractions (PhTX-II) were collected, lyophilized and used for biochemical/pharmacological 
characterization. To verify the degree of homogeneity, re-chromatography of PhTX-II was performed 
by the same chromatography system used in the fractionation step (reverse phase HPLC). The protein 
was concentrated by ultrafiltration through a YM-3 Amicom membrane and washed with water or 
ammonium bicarbonate 0.05 M, pH 8.0 followed by lyophilization. 
4.3. Electrophoresis 
Tricine SDS-PAGE in a discontinuous gel and buffer system was used to estimate the molecular mass 
of the PhTX-II PLA2, under reducing and non-reducing conditions [46]. The molecular mass markers 
used were (in kDa): phosphorylase B—94, albumin—67, ovalbumin—43, carbonic anhydrase—30, 
soybean trypsin inhibitor—20 and lysozyme—14. 
4.4. Determination of the Molecular Mass of the Purified Protein by Mass Spectrometry 
An aliquot (4.5 μL) of the PhTX-II PLA2 was inject by C18 (100 μm × 100 mm) RP-UPLC 
(nanoAcquity UPLC, Waters Corporation, Milford, MA, USA) coupled with nanoelectrospray tandem 
mass spectrometry on a Q-Tof Ultima API mass spectrometer (MicroMass/Waters Corporation, Milford, 
MA, USA) at a flow rate of 600 mL/min. The gradient was 0%–50% acetonitrile in 0.1% formic acid 
over 45 min. The instrument was operated in MS continuum mode and the data acquisition was from 
m/z 100–3000 at a scan rate of 1 s and an interscan delay of 0.1 s. The spectra were accumulated over 
about 300 scans and the multiple charged data produced by the mass spectrometer on the m/z scale were 
converted to the mass (molecular weight) scale using maximum-entropy-based software (1) supplied 
with Masslynx 4.1 software package. The processing parameters were: output mass range 6,000–20,000 Da 
at a “resolution” of 0.1 Da/channel; the simulated isotope pattern model was used with the spectrum blur 
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width parameter set to 0.2 Da and the minimum intensity ratios between successive peaks were 20% 
(left and right). The deconvoluted spectrum was then smoothed (2 × 3 channels, Savitzky Golay smooth) 
and the mass centroid values obtained using 80% of the peak top and a minimum peak width at half 
height of 4 channels. 
4.5. Analysis of Tryptic Digests 
The PhTX-II PLA2 was reduced (DTT 5 mM for 25 min to 56 °C) and alkylated (Iodoacetamide  
14 mM for 30 min) prior to the addition of trypsin (Promega’s sequencing grade modified). After trypsin 
addition (20 ng/μL in Ambic 0.05 M), the sample was incubated for 16 h at 37 °C. To stop the reaction, 
formic acid 0.4% was added and the sample centrifuged at 2500 rpm for 10 min. The pellet was  
discarded and the supernatant dried in a speed vac. The resulting peptides were separated by C18  
(100 μm × 100 mm) RP-UPLC (nanoAcquity UPLC, Waters Corporation, Milford, MA, USA)  
coupled with nanoelectrospray tandem mass spectrometry on a QTof Ultima API mass spectrometer  
(Micro Mass/Waters Corporation, Milford, MA, USA) at a flow rate of 600 nL/min. Before performing 
a tandem mass spectrum, an ESI/MS mass spectrum (TOF MS mode) was acquired for each HPLC 
fraction over the mass range of 100–2000 m/z, in order to select the ion of interest; subsequently,  
these ions were fragmented in the collision cell (TOF MS/MS mode). 
Raw data files from LC-MS/MS runs were processed using Masslynx 4.1 software package (Waters) 
and analyzed using the MASCOT search engine version 2.3 (Matrix Science Ltd., Mascot Server  
version 2.3, London, UK, 2012) against the snakes database, using the following parameters: peptide 
mass tolerance of ±0.1 Da, fragment mass tolerance of ±0.1 Da, and oxidation as variable modifications 
in methionine and trypsin as enzyme. 
4.6. Circular Dichroism 
Circular dichroism (CD) spectra of PhTX-II PLA2 was recorded with a JASCO model J-720-ORD 
306 spectropolarimeter equipped with a thermoelectric sample temperature controller (Peltier system) 
following standard procedures previously described [47]. After centrifugation at 4000 g for 5 min, 
samples (1–4 μM protein in 10 mM sodium phosphate, pH 8) were transferred to a 10-mm path-length 
quartz cuvette. Circular dichroism spectra in the wavelength range 260–200 nm were collected, using a 
bandwidth of 1 nm and a response time of 1 s. Data collection was performed at 25 °C with 50 nm/min 
scanning speed. At least 10 scans were accumulated for each sample, and all spectra were corrected by 
subtraction of buffer blanks. The estimation of secondary structure elements was performed using the 
CDNN Deconvolution software,version 2.1 (Applied Photophysics, Leatherhead, Surrey, UK, 2011) and 
Origin® 7.5 (version 7.5, OriginLab Corporation, Wellesley Hills, MA, USA, 2003) was used for 
graphics and analysis. 
4.7. Chemical Modifications 
Modification of His residues with p-Bromophenacyl Bromide (BPB) was carried out as previously 
described [35]. Briefly, 3 mg of PhTX-II PLA2 were dissolved in 1 mL of 0.1 M Tris-HCl containing 
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0.7 mM EDTA (pH 8.0) and 150 µL of BPB (1.5 mg/mL, in ethanol), and the mixture incubated for  
24 h at 25 °C. 
4.8. PLA2 Activity 
PLA2 activity was measured using the assay described by Cho and Kezdy, [48] and Holzer  
and Mackessy, [49] modified for 96-well plates. The standard assay mixture contained 200 µL of  
buffer (10 mM Tris-HCl, 10 mM CaCl2 and 100 mM NaCl, pH 8.0), 20 µL of substrate  
4-nitro-3-(octanoyloxy) benzoic acid (3 mM), 20 µL of water and 20 µL of PhTX-II PLA2 or modified 
with BPB (1 mg/mL) in a final volume of 260 µL. After adding proteins (20 µg) the mixture was 
incubated for up to 40 min at 37 °C, measuring absorbance at intervals of 10 min. The enzyme activity, 
expressed as the initial velocity of the reaction (Vo), was calculated based on the increase of absorbance 
after 20 min. The pH and optima temperature of the PhTX-II PLA2 were determined by incubating the 
enzyme in four buffers of different pH values (4–10) and in Tris-HCl buffer, pH 8.0, at different 
temperatures, respectively. The effect of substrate concentration (40, 20, 10, 5, 2.5, 1.0, 0.5, 0.3, 0.2 and 
0.1 mM) on enzyme activity was determined by measuring the increase of absorbance after 20 min of 
incubation in Tris-HCl buffer, pH 8.0 at 37 °C. All assays were done in triplicate and the absorbances at 
425 nm were measured with a VersaMax 190 multiwell plate reader (Molecular Devices, Sunnyvale, 
CA, USA). The protein concentration of PhTX-II was determined by the Bradford protein assay. 
4.9. Inhibition 
The inhibitory effect of EDTA or low molecular weight heparin from porcine intestinal  
(Mr 6000 Da) on pharmacological and enzymatic activities of PhTX-II PLA2 were assessed by 
incubating the enzyme with 1 mM solution of this chelating agent or a heparin : toxin molar ratio of 2:1 
for 30 min at 37 °C. The inhibition of PLA2 activity of PhTX-II by crotapotins F2 and F3 from  
Crotalus durissus collilinetaus also was evaluated by incubating the two proteins (1:1, w/w) for 30 min 
at 37 °C and then assaying the residual enzyme activity. 
4.10. Chick Biventer Cervicis Muscle Preparation (BCP) 
Animals were anesthetized with halothane and sacrificed by exsanguination. The biventer cervicis 
muscles were removed and mounted under a tension of 0.5 g, in a 5 mL organ bath (Automatic organ 
multiple-bath LE01 Letica Scientific Instruments, Barcelona, Spain) at 37 °C containing aerated  
(95% O2-5% CO2) Krebs solution (pH 7.5) of the following composition (mM): NaCl 118.70, KCl 4.70, 
CaCl2 1.88, KH2PO4 1.17, MgSO4 1.17, NaHCO3 25.00 and glucose 11.65. Contracture to exogenously 
applied acetylcholine (ACh; 110 μM for 60 s) and KCl (20 mM for 130 s) was obtained in the absence 
of field stimulation, before and after the addition of a single dose of PhTX-II PLA2 (0.35, 0.7 and  
1.4 μM). A bipolar platinum ring electrode was placed around the tendon, which runs around the nerve 
trunk supplying the muscle. Indirect stimulation was performed with a (MAIN BOX LE 12404 Panlab 
s.l. Powerlab AD Instruments Barcelona, Spain) stimulator (0.1 Hz, 0.2 ms, 3–4 V). Muscle contractions 
and contractures were isometrically recorded by force-displacement transducers (Model MLT0201 
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Force transducer 5 mg–25 g Panlab s.l. AD Instruments Pty Ltd., Barcelona, Spain) connected to a 
PowerLab/4SP (OUAD Bridge AD Instruments, Barcelona, Spain) [50]. 
4.11. Myotoxic Activity 
Groups of five Swiss mice (18–20 g) received an intramuscular injection (i.m.) of variable amounts 
of PhTX-II PLA2 (5, 20 and 50 μg) dissolved in 100 µL of PBS, in the gastrocnemius. A control group 
received 100 µL of PBS (0.12 M NaCl, 0.04 M sodium phosphate, pH 7.2). At different intervals of time 
(1, 3, 6, 9 and 24 h) blood was collected from the tail into heparinized capillary tubes, and the plasma 
creatine kinase (CK; EC 2.7.3.2) activity was determined by a kinetic assay (Sigma 47-UV,  
Sigma-Aldrich, St. Louis, MO, USA). Activity was expressed in U/L one unit defined as the 
phosphorylation of 1 µmol of creatine/min at 25 °C [51]. 
4.12. Edema-Forming Activity 
The ability of PhTX-II PLA2 to induce edema was studied in groups of five Swiss mice (18–20 g). 
Fifty µL of phosphate-buffered saline (PBS; 0.12 M NaCl, 0.04 M sodium phosphate, pH 7.2) with 
toxins (2, 5 and 10 µg/paw) were injected in the sub plantar region of the right footpad. The left  
footpad received 50 µL of PBS, as a control. The paw volume was evaluated plethysmographically  
(Model 7140 Plethysmometer Ugo Basile, Gemonio, Varese, Italy), immediately before the injection 
(basal) and at selected intervals of time (0.5, 1, 3, 6, 9 and 24 h). Edema-forming activity was expressed 
as the percentage of the increase in volume of the right foot pad in comparison to the left foot pad 
(control). The equation for calculation of the percentage of edema in toxins injected paw was:  
% edema = (((Tx × 100)/ To) − 100). Where Tx is the edema (volume) measured at each time interval 
and To is the volume of the paw (intact, zero time before toxins injection). The percentage of edema 
calculated was subtracted from the matched values at each time point in the saline injected hind  
paw (control) [52]. 
4.13. Statistical Analyses 
Results were reported as mean ± SEM. The significance of differences among means was assessed 
by analysis of variance followed by Dunnett’s test, when several experimental groups were compared 
with the control group. Differences were considered statistically significant if p < 0.05. 
5. Conclusions 
In conclusion, we have identified and characterized the PhTX-II enzyme, a new Asp-49 PLA2 
monomeric isolated from P. hyoprora venom. PhTX-II PLA2 causes neuromuscular blockade in avian 
neuromuscular preparations with a significant direct action on skeletal muscle function and additionally, 
also induced local edema and myotoxicity in mice. The enzymatic activity of PhTX-II contributes to this 
neuromuscular blockade and the induced local myotoxicity is dependent not only on enzymatic activity. 
Taken together, these results confirm the importance of the contribution of PhTX-II PLA2 in the 
envenomation by this snakebite, where this isoform is able to trigger higher myotoxicity and evidence 
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structural differences which are of particular value to understanding the complex structure-function 
relationships that govern this highly diverse group of snake venom proteins. 
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